A tale of the two PEGylated liposomal doxorubicins

Abstract

Hunghsueh Chou,1,4 Hao Lin,2,4 Jacqueline M Liu31Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, Linkou, Taiwan; 2Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Linkou, Taiwan; 3TTY Oncology Translational Research Center, TTY Biopharm, Taipei, Taiwan; 4Chang Gung University College of Medicine, Linkou, TaiwanWe are writing this letter in response to the article "Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era" by Berger et al and published in August 2014.1 This paper is one of the earliest reports of the outcome of using Lipodox® available in the Western medical literature.View original paper by Berger et alCorrigendum for this article has been published